title: Does sildenafil have protective effects against ovarian ischemia-reperfusion injury in rats?
abstract: OBJECTIVE
  The aim of this study was to evaluate the protective activity of sildenafil treatment against ischemia-reperfusion damage created experimentally in rat ovaries.
  
  
  METHODS
  For this study, 42 female Wistar rats were used, and the rats were separated randomly into six groups consisting of seven rats each: sham, torsion, torsion-detorsion, torsion-detorsion + saline, torsion-detorsion + sildenafil 0.7 mg/kg and torsion-detorsion + sildenafil 1.4 mg/kg. With the exception of the sham group, an ovarian torsion procedure was implemented in all other groups for 2 h. Then, a detorsion procedure was implemented to the groups for 2 h, with the exception of the torsion group. Medications were given intraperitoneally, one-half hour before the detorsion procedure in the saline, 0.7 and 1.4 mg/kg sildenafil groups. Finally, 2 ml of blood samples was drawn for markers of oxidative stress, while the ovaries which were torsioned for the histological examination were extracted from all rats.
  
  
  RESULTS
  According to the histopathological damage scores, the least damage was seen in the sham group and the most damage was seen in the torsion-detorsion group. The sildenafil treatment appeared to be effective in decreasing tissue damage; however, there were no differences between the dosages. Additionally, it was determined that the oxidative stress levels were higher in the torsion-detorsion group, while the sildenafil treatment caused a significant decrease in the oxidative stress levels.
  
  
  CONCLUSIONS
  The results of the current study showed that the sildenafil treatment can be effective in preventing tissue damage and oxidative stress induced by the ischemia-reperfusion created in rat ovaries.
authors.affiliation: Department of Gynecology and Obstetrics, Harran University School of Medicine, Yenisehir Campus, 63300, Sanlıurfa, Turkey, dr.aincebiyik@gmail.com.
authors.forename: Adnan
authors.initials: A
authors.lastname: Incebiyik
authors.forename: Ahmet
authors.initials: A
authors.lastname: Seker
authors.forename: Hakan
authors.initials: H
authors.lastname: Camuzcuoglu
authors.forename: Sezen
authors.initials: S
authors.lastname: Kocaslan
authors.forename: Aysun
authors.initials: A
authors.lastname: Camuzcuoglu
authors.forename: Nese Gul
authors.initials: NG
authors.lastname: Hilali
authors.forename: Mehmet
authors.initials: M
authors.lastname: Vural
authors.forename: Abdullah
authors.initials: A
authors.lastname: Taskin
authors.forename: Nurten
authors.initials: N
authors.lastname: Aksoy
mesh_terms: D000818:Animals; D005260:Female; D006801:Humans; D007511:Ischemia; D023421:Models, Animal; D010049:Ovarian Diseases / Q000150:complications / Q000188:drug therapy*; D010053:Ovary / Q000098:blood supply* / Q000187:drug effects*; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology; D010879:Piperazines / Q000494:pharmacology*; D011687:Purines / Q000494:pharmacology; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000378:metabolism / Q000517:prevention & control*; D000068677:Sildenafil Citrate; D013449:Sulfonamides / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D010879:Piperazines; D011687:Purines; D013449:Sulfonamides; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate